ONCAlert | Upfront Therapy for mRCC

Promising CheckMate-142 Data for Second-Line Ipilimumab Plus Nivolumab in mCRC

Michael J. Overman, MD
Published Online: 9:32 PM, Mon January 21, 2019

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the data presented at the 2019 Gastrointestinal Cancers Symposium for the phase II CheckMate-142 in previously treated patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC).

While this subset of patients only represents about 4% or 5% of the CRC population, it consistently shows great activity with immunotherapy, says Overman. This subset of patients has demonstrated activity with pembrolizumab (Keytruda), nivolumab (Opdivo), and now combinations such as nivolumab plus ipilimumab (Yervoy).

A large cohort of 114 patients with MSI-H or dMMR mCRC were treated with the nivolumab/ipilimumab combination in CheckMate-142. The response rate was about 50% with a consistent progression-free survival (PFS). Overman says that at 1 year, PFS was about 70%. This demonstrates a durable and high level of activity.

Another cohort looked at this combination in the frontline, showing similar activity. Overall, Overman concludes that this is an exciting combination with data across all lines in mCRC. Despite a lack in randomized trials for the frontline, he predicts there will be a randomized study for this combination in the future.

Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.